Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
BY PR Newswire
— 8:00 AM ET 08/25/2016
SAN DIEGO, California, August 25, 2016 /PRNewswire/ --
Regen BioPharma, Inc. ( RGBP
Loading...
Loading...
) , , is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.
"We are pleased with the progress being made by our advisor to identify potential partnerships that can support the growth needs of our several therapeutic assets including HemaXellerate, our most advanced asset for aplastic anemia and chemotherapy-induced myelosuppression, and our novel NR2F6 programs for immune oncology and autoimmune disorders," said David Koos, Ph.D., Regen's Chief Executive Officer. "Over the past year, there have been numerous partnering transactions that have occurred between large pharmaceutical companies and smaller biotechnology companies like Regen which demonstrate an appetite for investment in early stage companies with novel technologies which address significant markets. While we cannot guarantee success in signing a licensing arrangement, we believe our assets will be able to attract the sort of best in class partners which will maximize the Company's success and that strategic partnerships will play a major role in the further development of our assets."
Regen BioPharma's ( RGBP
Loading...
Loading...
) pipeline includes autologous cell therapies (HemaXellerate, dCellVax, tCellVax), universal donor cell therapy (ucVax) and small molecules (NR2F6 program). HemaXellerate is the subject of an Investigational New Drug Application (IND) and planned Phase I/II clinical trial that is intended to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia. The Company also intends to file an IND and pursue a Phase I/II clinical trial assessing HemaXellerate in patients suffering from chemotherapy-induced bone marrow suppression. Significant progress has been achieved with regards to Regen's NR2F6 Programs (a novel molecular switch or control center that modulates the immune system for which no known molecules that bind to it exist) in securing the intellectual property and conducting preclinical testing with the goal of entering the market with an oral drug following further development.
